1627 – Point-of-care test for diagnosis of Neisseria gonorrhoea, Chlamydia trachomatis and Trichomonas vaginalis infection in Aboriginal and Torres Strait Islander patients presenting at health services in areas with high sexually transmitted infection burden

Page last updated: 30 March 2022

Application Detail

Description of Medical Service

Rapid on-demand nucleic acid amplification test for use at point-of-care in clinics servicing remote communities enabling laboratory equivalent, on-the-spot diagnosis for Chlamydia trachomatis, Neisseria gonorrhoea, and/or Trichomonas vaginalis infection within 90 minutes, facilitating antibiotic treatment for patients and initiation of contact tracing.

Description of Medical Condition

Chlamydia trachomatis, Neisseria gonorrhoea and Trichomonas vaginalis are sexually transmitted bacterial infections, often asymptomatic, mostly affecting young people aged 15-29 years. Easily cured with antibiotics, untreated infection can cause pelvic inflammatory disease resulting in chronic abdominal pain, as well as increasing the risk of tubal infertility and ectopic pregnancy.

Reason for Application

New MBS items

Medical Service Type

Investigative

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1593 KB)
Application Form (Word 443 KB)

Consultation Survey

Consultation Survey (PDF 588 KB)
Consultation Survey (Word 68 KB)

PASC Consultation
PASC consultation closed

MSAC Consultation
MSAC consultation TBA – please subscribe to the MSAC Email Bulletin to be notified when consultation opens for this application

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

PICO Confirmation (PDF 1403 KB)
PICO Confirmation (Word 205 KB)

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

12-13 August 2021

ESC

-

MSAC

-